Results 131 to 140 of about 1,751 (155)

0856 Real-World Patient Insights on Low-Sodium Oxybate for Idiopathic Hypersomnia: Interim Results from LYRICAL

SLEEP
Abstract Introduction Low-sodium oxybate (LXB; Xywav®) is approved by the US Food and Drug Administration to treat excessive daytime sleepiness or cataplexy in patients ≥7 years of age with narcolepsy and adults with idiopathic hypersomnia (IH).
Caroleen Drachenberg, Jennifer Cline, Jennifer D’Souza, Christina Graham, Emily Kim, Meaghan Lawrence, Meagan Farrell, Grecia Sanchez, Donald Stull, Marisa Whalen, Jessica Alexander, Laura Herpel   +11 more
openaire   +1 more source

0852 Subjective Sleep Quality with Low-Sodium Oxybate Treatment in Idiopathic Hypersomnia: Results from the DUET Study

SLEEP
Abstract Introduction Jazz DUET (Develop hypersomnia Understanding by Evaluating low-sodium oxybate Treatment) is a phase 4, prospective, multicenter, single-arm, multiple-cohort, open-label study (NCT05875974) evaluating the effectiveness of low-sodium oxybate (LXB, Xywav®) treatment on outcomes ...
Richard Bogan, David Plante, Alyssa Cairns, Deborah Nichols, Teresa Steininger, Douglas Fuller, Sarah Akerman, Marisa Whalen, Nancy Foldvary-Schaefer   +8 more
openaire   +1 more source

0632 Design Elements for a Switch Study from High- to Low-Sodium Oxybate Evaluating Blood Pressure in Narcolepsy (XYLO)

SLEEP
Abstract Introduction High sodium intake can increase blood pressure (BP) and future cardiovascular risk. Individuals with narcolepsy have an elevated cardiovascular comorbidity burden before considering medication-specific risks.
William White, Wayne Macfadden, Christine Baranak, Deborah Nichols, Sarah Akerman, Virend Somers   +5 more
openaire   +1 more source

0851 Effectiveness and Safety of Low-Sodium Oxybate in Idiopathic Hypersomnia Participants: Results from the DUET Study

SLEEP
Abstract Introduction Introduction: Jazz DUET (Develop hypersomnia Understanding by Evaluating low-sodium oxybate Treatment) is a phase 4, prospective, multicenter, single-arm, multiple-cohort, open-label study (NCT05875974) evaluating the effectiveness of low-sodium oxybate (LXB, Xywav®) treatment on
David Plante, Alyssa Cairns, Logan Schneider, Deborah Nichols, Teresa Steininger, Douglas Fuller, M Kirby, Sarah Akerman, Jessica Alexander, Marisa Whalen, Chad Ruoff   +10 more
openaire   +1 more source

0831 Effectiveness and Safety of Low-Sodium Oxybate in Participants with Narcolepsy: Results from the DUET Study

SLEEP
Abstract Introduction Jazz DUET (Develop hypersomnia Understanding by Evaluating low-sodium oxybate Treatment) is a phase 4, prospective, multicenter, single-arm, multiple-cohort, open-label study (NCT05875974) assessing the effectiveness of low-sodium oxybate (LXB; Xywav®) treatment on daytime and ...
Logan Schneider, Chad Ruoff, David Plante, Deborah Nichols, Teresa Steininger, Douglas Fuller, M Kirby, Sarah Akerman, Jessica Alexander, Marisa Whalen, Alyssa Cairns   +10 more
openaire   +1 more source

0639 Long-term Safety and Timing of Adverse Events with Low-Sodium Oxybate in a Phase 3 Idiopathic Hypersomnia Study

SLEEP
Abstract Introduction Low-sodium oxybate (LXB; Xywav®) is approved by the US Food and Drug Administration for the treatment of idiopathic hypersomnia in adults. To examine the long-term safety of LXB in this population, this post hoc analysis evaluated treatment-emergent adverse events (TEAEs) over ...
Richard Bogan, Marisa Whalen, Stefanie Bronson, Douglas Fuller, Wayne Macfadden   +4 more
openaire   +1 more source

Abstract FR498: Impact of Switching From High- to Low-Sodium Oxybate on Ambulatory and Office Blood Pressure in Subgroups of People With Narcolepsy From the XYLO Study

Hypertension
Introduction: Excess sodium intake is strongly linked with hypertension and cardiovascular disease (CVD); people with narcolepsy (PwN) have increased CV risk. Hypothesis: Switching from high-sodium oxybate (SXB; Xyrem ® ; 6–9 g for ≥6 wks) to low-sodium ...
Virend Somers, Richard Kovacs, Jessica Alexander, Christine Baranak, Deborah Nichols, Jing Dai, Marisa Whalen, Akinyemi Ajayi, barbara hutchinson, Yves Dauvilliers, William White   +10 more
openaire   +1 more source

Long-term Safety During a Clinical Trial of Low-Sodium Oxybate in Participants With Narcolepsy With Cataplexy (P5-13.006)

Neurology, 2023
Richard Bogan, Nancy Foldvary-Schaefer, Roman Skowronski, Abby Chen, Michael Thorpy   +4 more
openaire   +1 more source

Effectiveness and Optimization of Low-Sodium Oxybate in Participants With Narcolepsy Switching From High-Sodium Oxybate: Interim Data from the Substitution of Equal Grams of Uninterrupted Xyrem to Xywav (SEGUE) Study (P5-13.003)

Neurology, 2023
Eileen Leary, Todd Kirby, Roman Skowronski, Kevin Xu, Craig Pfister, Wayne Macfadden   +5 more
openaire   +1 more source

Effects of Low-Sodium Oxybate on 24-Hour Total Sleep Time: Data From a Phase 3 Clinical Study in Adults With Idiopathic Hypersomnia (P5-13.001)

Neurology, 2023
Anne Marie Morse, Abby Chen, Teresa Steininger, Wayne Macfadden   +3 more
openaire   +1 more source